Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US90184D1000
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG006KDCHJ4
TWST
Twist Bioscience Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Twist Bioscience Corp
ISIN
US90184D1000
TICKER
TWST
MIC
XNAS
REUTERS
TWST.OQ
BLOOMBERG
TWST US
Tue, 03.11.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Lead Case No. 1:23-cv-01048-MN SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION (...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.10.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncolo...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.10.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG with SPR binding characterization. Twist Express Screenin...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.10.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth quarter and full year ended September 30, 2026, before the opening of the market on November 12, 2026. The company plans to hold a conference call and live audio webcast for...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist....
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its c...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third quarter ended June 30, 2026, before the opening of the market on August 3, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 27.05.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago,...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 5...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detail...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.02.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. TD Cowen 46th Annual Health Care Conference...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive p...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.02.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp L...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity awards, consisting of 107,742 restricted stock units (“RSUs”) and up to 7,127 performance stock units (“PSUs”), will be granted to 52...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the deta...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 12.01.2026       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the fiscal 2026...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.12.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco. The presentation will be webcast live and c...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Twist Bioscience
US90184D1000

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. If you currently own Twist stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to t...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers’ pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and co...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist, will participate in a fireside chat at the at 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 3:20 pm Eastern...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.11.2025       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that it has granted a total of 139,569 equity awards, consisting of 91,441 restricted stock units (“RSUs”) and up to 48,128 performance stock units (“PSUs”), to 41...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.10.2025       Twist Bioscience
US90184D1000

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. If you currently own Twist stock and acquired shares on or before December 20, 2018, you may be able to seek corporate governance reforms, the retur...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, before the opening of the market on November 14, 2025. The company plans to hold a conference call and live audio webcast for an...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.10.2025       Twist Bioscience
US90184D1000

NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. ...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the launch of Twist’s new Trinity Freestyle Fast Hybridization workflow for Element's AVITI™ sequencing platforms, a user-friendly, end-to-end seq...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.10.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced the publication in Science of the peer-reviewed paper, “Strengthening nucleic acid biosecurity screening against generative protein design tools,” led by Microsoft and co-authored with a consortium of scientific and industry experts including t...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.09.2025       Twist Bioscience
US90184D1000

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. ...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.09.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025 at 9:40 am Eastern Time in New York City. The company will also host one-on-one mee...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.09.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL). “With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researc...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.08.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the launch of a humanized transgenic (HuTg) mouse model to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery. “The...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 70,254 equity awards, consisting of 56,182 restricted stock units (“RSUs”)...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.07.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, before the opening of the market on August 4, 2025. The company plans to hold a conferenc...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.07.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today accelerated its Express turnaround time for all Twist Gene Fragments with a turnaround time starting at two business days for both adapters off and adaptors on configurations. “We continue to i...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element’s AVITI systems and Trinity flowcells with...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time i...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units (“RSUs”)...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.05.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.05.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.05.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage (“Atlas”). “There are many applications of synthetic DNA w...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the expanded launch of the Twist High Throughput (HT) Unique Dual Index (UDI) Adapter System to enable multiplexing and sample batching at scale. Indexing is a critical part of the lib...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.04.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist’s FlexPrep™ Ult...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.03.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnarou...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink